Bayer stock slips as Sunharbo moves from FDA approval to US launch

Bayer stock traded at 56.33 euros on Lang & Schwarz at 17:04 CET on Thursday, November 12, 0.76 percent below the Xetra close of Wednesday, November 11. The move followed a new commercial detail around Sunharbo, Bayer's recently approved stroke-prevention medicine.

The U.S. Food and Drug Administration approved Sunharbo, also known as asundexian, on November 9. Bayer announced the decision on November 10 and said the medicine should begin shipping in the United States between mid-November and late November. The approval covers adults with a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack, in combination with antiplatelet therapy.

Bayer describes Sunharbo as the first approved Factor XIa inhibitor in the United States. The company's FDA approval release says the drug is taken once daily at a 50-milligram dose. The launch moves the product from regulatory development into the commercial phase, where prescription uptake, reimbursement and distribution will determine its financial contribution.

Clinical evidence and market scope

The pivotal Phase 3 OCEANIC-STROKE study randomized 12,327 patients to Sunharbo or placebo, with both groups receiving antiplatelet therapy. Bayer reported ischemic stroke rates of 6.2 percent with Sunharbo and 8.4 percent with placebo, corresponding to a 26 percent reduction. Major bleeding rates were similar, while gastrointestinal bleeding was more frequent with Sunharbo.

The U.S. label targets secondary stroke prevention and does not cover stroke prevention in atrial fibrillation. Bayer said Sunharbo had already received approval in China on October 26, while applications remained under review in Europe and Japan as of November.

For investors, the next test is execution rather than another regulatory milestone. A successful US launch could help Bayer build a new cardiovascular revenue stream, but the commercial outcome will depend on patient eligibility, prescribing behavior and access to treatment.

European healthcare shares remain sensitive to regulatory decisions, trial readouts and drug-pricing expectations, while the DAX market environment provides the relevant German equity backdrop.

More news and analyses on Bayer stock.